An Economic Model to Assess the Cost Impact of Using Xpert Carba-R to Screen Carbapenemase-Producing Enterobacterales in Comparison with Standard of Care, in a National Health Service Setting
The analysis found Xpert Carba-R to be cost saving compared with media culture for CPE screening in high-risk patients. The model did not explore onwards transmission or the opportunity cost of releasing isolation spaces, so the cost savings are likely to be far greater than those demonstrated in this study.
Authors
- Ruth Pulikottil-Jacob (ORCID: https://orcid.org/0000-0003-0630-960X)
- Mondher Toumi (ORCID: https://orcid.org/0000-0001-7939-7204)
- Karin M. Butler
- Kara Watts
- Isaac Odeyemi
Institutions
- Aix-Marseille Université (FR)
- Wycombe General Hospital (GB)
- Leeds and York Partnership NHS Foundation Trust (GB)
Publication Details
- Journal
- Infectious Diseases and Therapy
- Published
- 2025-04-19
- DOI
- https://doi.org/10.1007/s40121-025-01141-2
- Citations
- 3
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 1.77
Funders
- Cepheid